These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

166 related items for PubMed ID: 11429885

  • 1. 3-amino-1,2,4-benzotriazine 4-oxide: characterization of a new metabolite arising from bioreductive processing of the antitumor agent 3-amino-1,2,4-benzotriazine 1,4-dioxide (tirapazamine).
    Fuchs T, Chowdhury G, Barnes CL, Gates KS.
    J Org Chem; 2001 Jan 12; 66(1):107-14. PubMed ID: 11429885
    [Abstract] [Full Text] [Related]

  • 2. Reduction of 3-amino-1,2,4-benzotriazine-1,4-di-N-oxide (tirapazamine, WIN 59075, SR 4233) to a DNA-damaging species: a direct role for NADPH:cytochrome P450 oxidoreductase.
    Fitzsimmons SA, Lewis AD, Riley RJ, Workman P.
    Carcinogenesis; 1994 Aug 12; 15(8):1503-10. PubMed ID: 8055626
    [Abstract] [Full Text] [Related]

  • 3. Toward hypoxia-selective DNA-alkylating agents built by grafting nitrogen mustards onto the bioreductively activated, hypoxia-selective DNA-oxidizing agent 3-amino-1,2,4-benzotriazine 1,4-dioxide (tirapazamine).
    Johnson KM, Parsons ZD, Barnes CL, Gates KS.
    J Org Chem; 2014 Aug 15; 79(16):7520-31. PubMed ID: 25029663
    [Abstract] [Full Text] [Related]

  • 4. Pharmacokinetics and bioreductive metabolism of the novel benzotriazine di-N-oxide hypoxic cell cytotoxin tirapazamine (WIN 59075; SR 4233; NSC 130181) in mice.
    Walton MI, Workman P.
    J Pharmacol Exp Ther; 1993 May 15; 265(2):938-47. PubMed ID: 8496834
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Potentiation of the cytotoxicity of the anticancer agent tirapazamine by benzotriazine N-oxides: the role of redox equilibria.
    Anderson RF, Shinde SS, Hay MP, Denny WA.
    J Am Chem Soc; 2006 Jan 11; 128(1):245-9. PubMed ID: 16390153
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Oxidative DNA base damage by the antitumor agent 3-amino-1,2,4-benzotriazine 1,4-dioxide (tirapazamine).
    Kotandeniya D, Ganley B, Gates KS.
    Bioorg Med Chem Lett; 2002 Sep 02; 12(17):2325-9. PubMed ID: 12161126
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Importance of P450 reductase activity in determining sensitivity of breast tumour cells to the bioreductive drug, tirapazamine (SR 4233).
    Patterson AV, Barham HM, Chinje EC, Adams GE, Harris AL, Stratford IJ.
    Br J Cancer; 1995 Nov 02; 72(5):1144-50. PubMed ID: 7577460
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Radical properties governing the hypoxia-selective cytotoxicity of antitumor 3-amino-1,2,4-benzotriazine 1,4-dioxides.
    Anderson RF, Shinde SS, Hay MP, Gamage SA, Denny WA.
    Org Biomol Chem; 2005 Jun 07; 3(11):2167-74. PubMed ID: 15917906
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. A mass spectrometry study of tirapazamine and its metabolites. insights into the mechanism of metabolic transformations and the characterization of reaction intermediates.
    Zagorevskii D, Song M, Breneman C, Yuan Y, Fuchs T, Gates KS, Greenlief CM.
    J Am Soc Mass Spectrom; 2003 Aug 07; 14(8):881-92. PubMed ID: 12892912
    [Abstract] [Full Text] [Related]

  • 18. Characterization of radicals formed following enzymatic reduction of 3-substituted analogues of the hypoxia-selective cytotoxin 3-amino-1,2,4-benzotriazine 1,4-dioxide (tirapazamine).
    Shinde SS, Maroz A, Hay MP, Patterson AV, Denny WA, Anderson RF.
    J Am Chem Soc; 2010 Mar 03; 132(8):2591-9. PubMed ID: 20141134
    [Abstract] [Full Text] [Related]

  • 19. The 2-nitroimidazole EF5 is a biomarker for oxidoreductases that activate the bioreductive prodrug CEN-209 under hypoxia.
    Wang J, Foehrenbacher A, Su J, Patel R, Hay MP, Hicks KO, Wilson WR.
    Clin Cancer Res; 2012 Mar 15; 18(6):1684-95. PubMed ID: 22167409
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.